Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

ImmunityBio Discovered Novel Anktiva for Non-Muscle Invasive Bladder Cancer

ImmunityBio has developed a groundbreaking treatment for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), called Anktiva. This innovative therapy combines Anktiva (N-803) with Bacillus Calmette-Guérin (BCG).

Anktiva is a novel IL-15 superagonist complex that triggers the activation and proliferation of NK cells, CD8+ killer T cells, and CD4+ T helper cells. It mimics the natural properties of dendritic cells, enhancing the generation of memory killer T cells, which are specifically trained to recognise and attack cancer cells. 

Compared to native IL-15, Anktiva demonstrates improved pharmacokinetics, longer persistence in lymphoid tissues, and enhanced anti- tumour activity in vivo.

By leveraging this unique mechanism of action, Anktiva initiates a comprehensive immune response against cancer cells, resulting in durable complete responses. This approach marks a significant advancement in immunotherapy, moving beyond solely targeting T cells. 

The combination of immune cell proliferation and activation, coupled with the induction of T cell memory, forms the basis of a promising therapeutic approach applicable across various tumour types.

The approval of Anktiva represents a potential paradigm shift in NMIBC treatment, offering hope for improved outcomes and potentially reshaping the standard of care for bladder cancer patients.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024